ADAPT™ (Automated Discovery of Adapted Protein Targets) in-silico technology for the rapid identification of medically important or otherwise specialized genes in any organism by identifiying genes that display evidence of having undergone adaptive evolution. We have shown experimentally that these evolutionarily 'fine-tuned' genes play important roles in the organism's biology, and since all organisms undergo adaptive evolution, the system is widely applicable. ADAPT can be used to identify candidate gene targets for: therapeutic, agriculturalbiotechnology, industrial biotechnology and environmental biotechnology applications.

Electric Genetics has optimized this system to discover novel drug target candidates in bacterial, fungal and protozoal pathogenes. ADAPT incorporates sophisticated tools to perform large-scale searches and produces a list of likely drug targets and has been shown to have a very high success-rate in a proof-of-concept study performed on a major bacterial pathogen. While the genomic data necessary to perform these tests on is only available for bacteria to date, the Company can leverage its EST-clustering technology to produce "virtual genes" for other organisms that are not as well represented in genomic databases. This strategy has already proven effective for the malaria parasite.